GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms

GNE-493 is a novel PI3K/mTOR dual inhibitor with improved metabolic stability, oral bioavailability, and excellent pharmacokinetic parameters. Here GNE-493 potently inhibited viability, proliferation, and migration in different primary and established (LNCaP and PC-3 lines) prostate cancer cells, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Lu, Zhang, Wei, Yao, Ming-Yu, Tian, Ye, Xue, Bo-xin, Tao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927604/
https://www.ncbi.nlm.nih.gov/pubmed/35296639
http://dx.doi.org/10.1038/s41420-022-00911-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927604/
https://www.ncbi.nlm.nih.gov/pubmed/35296639
http://dx.doi.org/10.1038/s41420-022-00911-y

Ejemplares similares